We are proud to announce that three members of our team have been recognized by Managing IP. Dr. Jacqueline Lui and Ms. Pauli Wong have been recognized as a Patent Star and Mr. Eddie Ho as a Rising Star by Managing IP. These prestigious awards acknowledge their exceptional expertise and invaluable contributions to the field of intellectual property.

Dr. Lui is widely recognized as a leading expert in patent law, specializing in cross-jurisdiction patent prosecution and strategy. With over 20 years of experience in IP, she has provided invaluable guidance to startups, Fortune 500 companies, and HK/Nasdaq-listed companies. Her expertise encompasses various critical areas, including IP strategy, portfolio management, technology transfer, due diligence, and enforcement. Dr. Lui's exceptional track record and unwavering commitment to excellence have solidified her reputation as a trusted advisor in the field.

Ms. Pauli Wong oversees the patent drafting team at Eagle IP and assists local and international clients with patent prosecution across a wide range of technology fields. She helps clients navigate IP rights, portfolio management, and global filing strategy for innovations in areas like biotechnology, medical devices, and robotics. Pauli is passionate about empowering Hong Kong innovators, leveraging her ability to quickly understand new technologies, meticulous prosecution skills, strategic business acumen, and commitment to client service.

Mr. Eddie Ho is a qualified Chinese Patent Attorney and has quickly amassed extensive experience drafting and prosecuting patent applications in a broad range of areas, including biology, biotechnology, medical devices, diagnostics, material science, engineering, and software. He helps inventors and companies manage and navigate complex patent portfolios and is exceptionally strong at inter-disciplinary technologies.

Let us come together to celebrate this well-deserved accolade for Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho and to recognize their exceptional dedication to the dynamic world of intellectual property.

我們過去活動

Recommended Insights

China Top 50 Case of 2019: How a Functional Feature is Construed Greatly Impacts Protection Scope - Shimano KK v. SENSAH

2020年7月20日
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

What is the difference between an Invention Patent and a Utility Model Patent?

2021年8月13日
There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
Top crossarrow-right